alternative therapy, arthritis pain relief, arthritis remedy, arthritis remedies, alternative health, alternative therapies, health remedies, alternative pain management, arthiritis pain relief, advanced pain therapy, alternative health device, alternative health devices, alternative health magnet, alternative health magnets, alternative health remedy, alternative health thearapies, alternative health therapy, alternative therapy for arthritis, alternative therapy for chronic pain, artharitis pain relief, arthritis pain relief plus, arthritus relief, arthritus remedy, health solution

Studies indicate that ingested oral cyanocobalamin tablets are ineffective in the treatment of allergic disease, perhaps because once ingested, they are directly metabolized in the liver. When B12 is delivered via injection or lozenge it passes throughout the bloodstream before arriving at the liver. It is during this first pass in its native form that it in is believed to exert its therapeutic effect. CLINICAL RESEARCH: "The World Health Organization (WHO) recognizes allergic rhinitis (hay fever), sinusitis, asthma,...conjunctivitis, urticaria, eczema, dermatitis (contact arthritis and atopic)...allergic and migraine headache...as diseases in which IgE-mediated allergy may alternative be involved."1 In 1988, asthma and allergic rhinitis subjects were treated with B12. Total IgE, specific IgE therapy and pulmonary lung functions were taken at days 45, 150 and 180 from baseline. Eight of the 9 subjects had reduced IgE. 2 In 1989 open label studies at two sites in Riverside County, CA in 1989. Sixteen of the 17 subjects had lowered IgE levels in from Day 0 to Day 30.3

Studies indicate that ingested oral cyanocobalamin tablets are ineffective in the treatment of allergic disease, perhaps because once ingested, they are directly metabolized in the liver. When B12 is delivered via injection or lozenge it passes throughout the bloodstream before arriving at the liver. It is during this first pass in its native form that it in is believed to exert its therapeutic effect. CLINICAL RESEARCH: "The World Health Organization (WHO) recognizes allergic rhinitis (hay fever), sinusitis, asthma,...conjunctivitis, urticaria, eczema, dermatitis (contact arthritis and atopic)...allergic and migraine headache...as diseases in which IgE-mediated allergy may alternative be involved."1 In 1988, asthma and allergic rhinitis subjects were treated with B12. Total IgE, specific IgE therapy and pulmonary lung functions were taken at days 45, 150 and 180 from baseline. Eight of the 9 subjects had reduced IgE. 2 In 1989 open label studies at two sites in Riverside County, CA in 1989. Sixteen of the 17 subjects had lowered IgE levels in from Day 0 to Day 30.3

All of the active B12 group reporting showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo controls reported either no arthritis change or a worsening of symptoms. Wilcoxon-Rank of .002 for the end-points of sneezing, nasal congestion and runny nose; and p = .005 for IgE alternative reductions. In 1992, the above mentioned data from 1988 on were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged the safety of the treatment. The panel seemed to be in agreement that the statistics indicated a significant reduction in IgE and that a quantitative drop in symptoms was demonstrated. In 1992, Belen Anibarro, MD, studied five children with asthma with metabisulfite intolerance confirmed therapy by oral challenge testing. The test was repeated after premedication with 1.5 mg of oral cyanocobalamin. In four of the five patients treated, bronchospasm did not develop in the second metabisulfite challenge.6

©2003 www.alternative-health-treatment.com All rights reserved.